Australia End Stage Renal Disease Market Size & Outlook
Related Markets
Australia end stage renal disease market highlights
- The Australia end stage renal disease market generated a revenue of USD 3,428.0 million in 2023 and is expected to reach USD 7,991.7 million by 2030.
- The Australia market is expected to grow at a CAGR of 12.9% from 2024 to 2030.
- In terms of segment, dialysis was the largest revenue generating treatment type in 2023.
- Dialysis is the most lucrative treatment type segment registering the fastest growth during the forecast period.
End stage renal disease market data book summary
| Market revenue in 2023 | USD 3,428.0 million |
| Market revenue in 2030 | USD 7,991.7 million |
| Growth rate | 12.9% (CAGR from 2023 to 2030) |
| Largest segment | Dialysis |
| Fastest growing segment | Dialysis |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Transplant, Dialysis |
| Key market players worldwide | Nipro Corp, Fresenius SE & Co KGaA, Baxter International Inc, Medtronic PLC, B. Braun, BD, Asahi Kasei Corp, Cantel Medical, Nikkiso Co Ltd, JMS Support Japan |
Other key industry trends
- In terms of revenue, Australia accounted for 3.1% of the global end stage renal disease market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China end stage renal disease market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 21,945.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
End Stage Renal Disease Market Scope
End Stage Renal Disease Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| JMS Support Japan | View profile | 11-50 | Tokyo, Tokyo, Japan, Asia | https://jms-support.jp |
| Cantel Medical | View profile | 1001-5000 | Little Falls, New Jersey, United States, North America | http://www.cantelmedical.com |
| BD | View profile | 10001+ | Franklin Lakes, New Jersey, United States, North America | https://www.bd.com |
| Nikkiso Co Ltd | View profile | 8529 | 4-20-3, Ebisu, Shibuya-ku, Tokyo, Japan, 150-6022 | http://www.nikkiso.co.jp |
| Nipro Corp | View profile | 39713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | http://www.nipro.co.jp |
| B. Braun | View profile | 10001+ | Chapeltown, Sheffield, United Kingdom, Europe | https://www.bbraun.co.uk |
| Asahi Kasei Corp | View profile | 48897 | 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, Japan, 101-8101 | http://www.asahi-kasei.co.jp |
| Fresenius SE & Co KGaA | View profile | 193865 | Else-Kroener-Strasse 1, Bad Homburg, HE, Germany, 61352 | https://www.fresenius.com |
| Medtronic PLC | View profile | 95000 | Lower Hatch Street, 20 On Hatch, Dublin, Ireland, 2 | https://www.medtronic.com |
| Baxter International Inc | View profile | 60000 | One Baxter Parkway, Deerfield, IL, United States, 60015 | https://www.baxter.com |
Australia end stage renal disease market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to end stage renal disease market will help companies and investors design strategic landscapes.
Dialysis was the largest segment with a revenue share of 68.89% in 2023. Horizon Databook has segmented the Australia end stage renal disease market based on transplant, dialysis covering the revenue growth of each sub-segment from 2018 to 2030.
According to the Australian Institute of Health and Welfare, in 2018, 16,800 people died due to the CKD. 70% of the CKD hospital admission were aged at 65 years or above. Kidney’s Health Australia’s Primary Care Education Advisory Committee has issued a handbook.
The CKD Management in Primary Care featuring information such as treatment algorithms, nephrology referral guidelines and medication advice and treatment targets.
Thus, increasing government initiatives and rising prevalence of CKD are few factors contributing toward market growth.
Reasons to subscribe to Australia end stage renal disease market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia end stage renal disease market databook
-
Our clientele includes a mix of end stage renal disease market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia end stage renal disease market , including forecasts for subscribers. This country databook contains high-level insights into Australia end stage renal disease market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia end stage renal disease market size, by treatment type, 2018-2030 (US$M)
Australia End Stage Renal Disease Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
